
XVIVO - A major challenge triggers a major opportunity

Q2 reveals an unusual period of a significant slowdown for the US lung business. Apart from the surprising magnitude it also comes with a limited near-term transparency. This is a major surprise for both XVIVO, investors and some important customers. Despite a slow Q3 period we regard this as a very unusual investment opportunity ahead of normalised growth, demand and increasing launch support after 2026.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

XVIVO - A major challenge triggers a major opportunity